Dr. John Cush RheumNow
4 years 5 months ago
Study of 1899 ankylosing spondylitis pts(10 RCTs) shows TNFi resp can be predicted - 34% had major resp vs 34% w/ no resp @ wk12. A major resp increased w/ higher CRP, Pt Global & BASDAI-Q2 score & decr w/ higher BMI & BASFI https://t.co/DrT7EVcZi0 https://t.co/CcFicTM0Mo
Dr. John Cush RheumNow
4 years 5 months ago
Your Lupus Questions from RNL 2022
Rheumatologists questions for Dr. Jack Cush
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/845D5KfUzY https://t.co/RtKopcTfiY
Dr. John Cush RheumNow
4 years 5 months ago
Baricitinib Efficacy in Alopecia Areata
https://t.co/6jYX5sPW44 https://t.co/Hvalig6U7V
Dr. John Cush RheumNow
4 years 5 months ago
Your Rheumatoid Questions from RNL 2022
Rheumatologists questions for Dr. Jack Cush QD
Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/sHBMKNvoXQ https://t.co/jcQgOIz7xt
Dr. John Cush RheumNow
4 years 5 months ago
JAMA reports another study showing safety of COVID-19 vaccination during pregnancy with no incr in adverse pregnancy outcomes. Scand study of 157,521 births - 0.7%, 8.3%, 9.1% of were vaxD during 1st, 2nd, 3rd trimesters https://t.co/dZuabwr1Sf https://t.co/CtzMoEV1Ee
Dr. John Cush RheumNow
4 years 5 months ago
Canadian population study shows that mRNA COVID-19 vaccination DURING 2nd &3rd trimester of pregnancy did not increase rate of adverse peripartum outcomes (vs no vax or vax post-Preg). Comparison of 97 590 Preg vs 44 815 non-preg https://t.co/n7nWcoLw4S https://t.co/uiVOg5A1S8
Socioeconomic status (SES) often associates with poorer outcomes in systemic lupus erythematosus (SLE) patients; and a current study suggests this is unrelated to healthcare access issues.
Dr. John Cush RheumNow
4 years 5 months ago
Free Teaching PDF on "What is Rheumatoid Arthritis" from JAMA https://t.co/EGdq1jbjzJ
Dr. John Cush RheumNow
4 years 5 months ago
Join us for Tuesday Night Rheumatology on April 5 at 7pm ET.
Register today!
https://t.co/ocaWwqB51x https://t.co/IPsf45UV0V
In a phase III trial, oral tacrolimus (Prograf) proved non-inferior to intravenous cyclophosphamide for treating lupus nephritis, researchers said.
Among 158 patients randomized to tacrolimus, 83.0% achieved complete or partial responses after 24 weeks versus 75.0% of 156 assigned to intravenous cyclophosphamide, according to Zhaohui Zheng, MD, of Zhengzhou University in China, and colleagues.
Dr. John Cush RheumNow
4 years 5 months ago
Differences in Biologic Persistence in PsO and PsA
Administrative claims analysis of biologic use in PsO and PsA in French health insurance databases shows that despite widespread biologic use, overall drug persistence was low for PsO and PsA biologics.
https://t.co/PtrXu9xyFa https://t.co/RWciF4DqXj
Dr. John Cush RheumNow
4 years 5 months ago
Metanalysis of 51 studies shows that chronic noninflammatory MSK pain is associated with impaired sexual function; compromised intimate relationships; and issues of sexual identity, body image, and self-worth https://t.co/VKHEMWiQZb https://t.co/OXhNSQF8Vc
Dr. John Cush RheumNow
4 years 5 months ago
Study of 119 SLE pts (30 w CKD) shows urinary galectin-3 binding protein as a biomarker, increased w/ active LN, significantly (p<0.001)correlating w/ SLEDAI, SLICC RAS, histologic activity; higher in proliferative vs membranous LN (p=0.04) https://t.co/s8mRnfxIj6 https://t.co/s1OoiRy6Xi
